Acne Drug Denifanstat Maintained Skin Clearing Results
A year-long clinical trial showed that the medication effectively kept acne symptoms at bay for hundreds of participants.
Updated on Sept. 30, 2026 in Beauty
Live Poll
Is long-term use of new acne medications a risk you would be willing to take?
Researchers have reported 52-week findings from a phase 3 open-label extension study of denifanstat, an acne treatment. The data confirms sustained improvements in skin clearance for patients who remained on the medication.
Why it matters
Managing acne often requires long-term maintenance, and this trial provides evidence that denifanstat may offer a durable option for skin health. These results characterize how the drug performs over a full year, informing future treatment decisions for those with chronic acne.
In a 52-week phase 3 open-label extension study of 239 patients, 57.8% of those on continuous denifanstat achieved treatment success. Success was defined as a two-point improvement in the Investigator's Global Assessment score, with efficacy observed to plateau between weeks 24 and 36.
The players
EADV Congress
An annual international medical meeting where leading dermatologists and researchers share advancements in skin health and treatment protocols.
Sagimet
A biopharmaceutical company focused on the development of fatty acid synthase inhibitors for various metabolic and dermatological conditions.
The details
Denifanstat works by inhibiting fatty acid synthase, a mechanism that lowers sebum production in the skin. By reducing this excess oil, the drug limits both inflammatory mediators and the primary food source used by Cutibacterium acnes. This approach targets the root biological drivers of acne, helping to maintain clearer skin over the course of the year-long trial.
Timeline
Week 12: Patients originally receiving a placebo were switched to the denifanstat treatment group.
Weeks 24-36: Efficacy results were observed to plateau for study participants.
September 30, 2026: Trial results were officially presented at the EADV Congress.
Health Landscape
This study advances the field of fatty acid synthase (FASN) inhibition, offering a distinct mechanism compared to traditional acne therapies like retinoids or antibiotics. It adds to the growing body of research exploring how metabolic regulation can serve as a long-term solution for acne.
These results provide insight into the potential for long-term acne management, which is a common topic to discuss during dermatology appointments. If you are exploring new treatment options, it is worth asking your physician about emerging metabolic therapies and their expected safety profiles.
The takeaway
Denifanstat has demonstrated consistent acne control over 52 weeks by targeting the skin's oil production mechanism. Patients interested in novel approaches to chronic skin concerns should monitor future developments and consult with a dermatologist about emerging treatment options.
Further reading
For more information on the latest innovations in skin treatments, visit Beauty.
More information
View the Sagimet official clinical trial results announcement for full details.
Source note: This article includes information reported by Hcplive.
Live Poll
Is long-term use of new acne medications a risk you would be willing to take?
